Novel therapeutic approaches that have been used in the treatment of allergic rhinitis and asthma include: omalizumab, alternate immunotherapy routes such as sublingual, modified allergen immunotherapy vaccines, anti-interleukin 5 (mepolizumab), interleukin-4 variant (pitrakinra) and tumor necrosis factor (TNF-α) blocking agents. This evidence concerns the gene TNF and allergic rhinitis.